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Repeated low-level exposures to biological agents could occur before or after the reme-
diation of an environmental release. This is especially true for persistent agents such as
B. anthracis spores, the causative agent of anthrax. Studies were conducted to examine
aerosol methods needed for consistent daily low aerosol concentrations to deliver a low-
dose (less than 106 colony forming units (CFU) of B. anthracis spores) and included a pilot
feasibility characterization study, acute exposure study, and a multiple 15 day exposure
study. This manuscript focuses on the state-of-the-science aerosol methodologies used
to generate and aerosolize consistent daily low aerosol concentrations and resultant low
inhalation doses to rabbits. The pilot feasibility characterization study determined that the
aerosol system was consistent and capable of producing very low aerosol concentrations.
In the acute, single day exposure experiment, targeted inhaled doses of 1× 102, 1× 103,
1× 104, and 1× 105 CFU were used. In the multiple daily exposure experiment, rabbits
were exposedmultiple days to targeted inhaled doses of 1× 102, 1× 103, and 1× 104 CFU.
In all studies, targeted inhaled doses remained consistent from rabbit-to-rabbit and day-
to-day. The aerosol system produced aerosolized spores within the optimal mass median
aerodynamic diameter particle size range to reach deep lung alveoli. Consistency of the
inhaled dose was aided by monitoring and recording respiratory parameters during the
exposure with real-time plethysmography. Overall, the presented results show that the
animal aerosol system was stable and highly reproducible between different studies and
over multiple exposure days.
Keywords: Bacillus anthracis, inhalation exposures, low-dose, subchronic exposures, spores, anthrax, aerosol
system
INTRODUCTION
Risk-based site-speciﬁc decision making for biothreat agents such
asBacillus anthracis poses unique challenges because of the adverse
combination of high persistence and high lethality.B. anthracis is a
Gram-positive, rod-shaped, facultative anaerobic, spore-forming
bacterium that is very stable in the environment (Inglesby et al.,
1999, 2002). Each potential B. anthracis exposure route (gastroin-
testinal, cutaneous, and inhalation) manifests itself in different
clinical symptoms,with inhalational anthrax being the most lethal
(Dixon et al., 1999). The B. anthracis Ames spore size ranges from
1.14 to 2.27μm in length (mean 1.52± 0.19) and 0.7–1.0μm
in diameter (mean 0.81± 0.06; Carrera et al., 2007) making it
the ideal size for inhaling deep into the human alveolar spaces
(Schlesinger, 1985; Hinds, 1999). Inhalation exposure can result
from spores that aerosolize upon the initial release as well as sub-
sequent re-aerosolization after settling on surfaces (Weis et al.,
2002). Given the high lethality of B. anthracis spores from the
inhalation route of exposure, the risk evaluation of contaminated
sites requires the ability to model the inhalation hazard posed
by spores that may remain on surfaces prior to or subsequent to
decontamination.
Successful inhalation aerosol exposure studies targeting low-
doses and the effects of multiple doses are needed to improve the
understanding of the potential risks associated with low levels of
inhaled spores. The principles used when generating, sizing, quan-
tifying, and sampling aerosols of inert materials also hold true for
bioaerosols, i.e., for aerosolizing materials of biological origin. In
light of this, the principles and techniques used for bioaerosols,
including highly infectious and lethal bacteria like B. anthracis,
have changed little in the last 60 years (Henderson, 1952; May,
1973; Stephenson et al., 1988; Cox and Wathes, 1995; Reponen
et al., 1997; Roy and Pitt, 2006). One of the major limitations
encountered when sampling infectious bioaerosols for dose deter-
mination is that the method must account for the viability of the
organism. Multiple techniques are available to quantify microor-
ganisms after sample collection such as direct microscopic count,
turbidity measurements, polymerase chain reaction, gravimetric
weight measurement, and culture. However, for spore-forming
microorganisms such as B. anthracis, the culture method is used
to distinguish viable from non-viable cells.
Limited low-dose-response data for B. anthracis continues
to challenge the development of effective risk-based approaches
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for potential contamination events (Wilkening, 2006; Gutting
et al., 2008). With some exceptions (Druett et al., 1953), his-
torical B. anthracis inhalation exposure studies with published
dose-response data relied on high doses that were associated with
multiple times the median lethal doses (LD50) to ensure lethality
in control animals (Galloway et al., 2004; Oscherwitz et al., 2010;
Yee et al., 2010). Earlier studies were conducted with a variety of
test species (e.g., guinea pigs, rabbits, various non-human primate
species) and exposure parameters such as differing B. anthracis
strains, varying routes of exposure, and numerous aerosol parti-
cle sizes (Fellows et al., 2001; Lawrence et al., 2009; Levy et al.,
2011). However, very few published animal exposure studies
include adequate dose ranges for low-dose extrapolation and suf-
ﬁcient descriptions of exposure products to allow for dosimetric
adjustments.
In view of the limited low-dose exposure data and the critical
need to support risk-based site-speciﬁc decision making, exposure
studies targeting low-doses were initiated in the rabbit model.
A pilot characterization study was ﬁrst conducted to determine
whether it was feasible to deliver low-doses of B. anthracis Ames
strain spores via the inhalation route in the animal aerosol system.
After achieving consistent results in the pilot study, both an acute
exposure study and multiple daily low-dose inhalation exposure
studywere conducted.Thismanuscript details the complex aerosol
design and techniques utilized to achieve the required consistent
low-doses on multiple exposure days.
MATERIALS AND METHODS
CHALLENGE MATERIAL
The B. anthracis Ames strain spores were prepared and character-
ized at Battelle (Columbus, OH, USA) and were stored at 4–8˚C
in sterile water (Thermo Scientiﬁc HyClone, Logan, UT, USA)
with 1.0% phenol (Sigma-Aldrich, St. Louis, MO, USA). Prior to
use, the spores were washed with endotoxin-free water four times
and were diluted to the appropriate concentration in endotoxin-
free sterile water and 0.01% Tween 20. The spore suspensions
contained less that 5% vegetative cells and debris and over 95%
were refractile under examination with phase contrast microscopy
(Leica Microsystems, Wetzlar, Germany). Prior to aerosolization,
the spores were enumerated (as described in Sample Analysis) and
diluted to the proper concentration required to yield the targeted
dose. The ﬁnal concentrations of the nebulizer samples were tar-
geted to be 1× 104, 1× 105, 1× 106, and 1× 107 colony forming
units (CFU)/mL depending on the study.
INHALATION SYSTEM
The inhalation system used is similar in design and operation to
those used at the U.S. Army Medical Research Institute of Infec-
tious Diseases (USAMRIID; Hartings and Roy, 2004; Roy and Pitt,
2006). The aerosol system was operated within a self-contained
Class III biological safety cabinet (BSC III) as diagrammed in
Figure 1.
Aerosol generation subsystem
Air was supplied to the system by an in-house air system ﬁltered
through two high efﬁciency particulate air (HEPA) capsule ﬁlters
(Pall Corp, Port Washington, NY, USA) and a carbon ﬁlter (Pall
Corp, Port Washington, NY, USA). The air was split into dilution
airﬂow of approximately 8.6 L/min and a nebulizer/bypass airﬂow
of approximately 7.5 L/min, maintained by mass ﬂow controllers
(MFC, Sierra, Monterey, CA, USA). The MFC were calibrated
prior to use. The dilution air was humidiﬁed via a bubbler as
needed to maintain humidity within a desired range of 53–83% as
required per standard operating procedure for the aerosol system.
A modiﬁed Microbiological Research Establishment type three-
jet Collison nebulizer (BGI, Waltham, MA, USA) with a precious
ﬂuid jar (BGI, Waltham, MA, USA) was used to generate a con-
trolled delivery of aerosolized B. anthracis spores, from a liquid
suspension. Collison nebulizers are designed to generate aerosols
having an approximate mean diameter of 1–2μm. The nebulizer
was characterized and ﬂow veriﬁed for a pressure that results
in an approximately 7.5 L/min ﬂow, which normally is approxi-
mately 172,375–248,220 Pa (or 25.0–36.0 pounds per square inch),
Collison nebulizer dependant.
Delivery subsystem
After the agent aerosol was generated by the Collison nebulizer, it
exited the Collison and traveled down a 3.75-cm diameter, 40 cm
long stainless steel cylinder (mixing tube) that mixed the aerosol
with dilution air. The aerosol then entered the top of the expo-
sure chamber through another cylinder with a tapered 14 cm long
slit on each side. The total airﬂow entering the exposure cham-
ber was approximately 16 L/min. The aerosol entered the chamber
through these slits to ﬁll the exposure chamber, washed over the
exposure target (muzzle or head), and was then exhausted out of
the exposure chamber through another cylinder at the bottom that
contained slots on two sides, each 19.5 cm in length. The aerosol
was pulled through the chamber using a vacuum pump (GAST,
Benton Harbor, MI, USA) that maintained a slight negative pres-
sure (from −0.25 to −0.01 inches of water) within the exposure
chamber, as measured using a differential pressure gage (Mag-
nehelic, Dwyer Instruments, Inc., Michigan City, IN, USA). The
exhaust aerosol was ﬁltered by two HEPA cartridge ﬁlters (Pall
Corp, Port Washington, NY, USA) before exiting the system into
the BSC III.
Exposure chamber
The exposure chamber was a plexiglass box with inter-
nal dimensions of approximately 20.5 cm× 20.5 cm× 40 cm
(Length×Width×Height). A port approximately 15 cm in diam-
eterwas located on one side of the chamberwhere an animal’s head
or muzzle entered into the exposure chamber. Rubber dental dam
was stretched across the opening and held in place with an o-ring
gasket. The animal’smuzzlewas pushed through a small hole in the
dental dam, producing a seal to prevent leakage around the open-
ing prior to aerosol generation. Four additional ports were located
in the chamber; two 1/4 inch diameter ports for collection of
aerosol samples [one for enumerationof spores andone for aerosol
particle sizingwith anAerodynamicParticle Sizer (APS) spectrom-
eter (Model 3321; TSI, Inc., Shoreview, MN, USA)], one 3/4 inch
diameter port to measure temperature and humidity (Tempera-
ture Stick, Testo, Sparta, NJ, USA) and one 1/4 inch diameter port
to measure the differential pressure within the exposure cham-
ber in relation to the surrounding atmosphere within the BSC III.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org June 2012 | Volume 2 | Article 71 | 2
Barnewall et al. Achieving low-dose inhalation exposures
FIGURE 1 | Diagram of the inhalation exposure system used throughout
the testing. Diagram shows all subsystems.A is the aerosol generator,
Collison nebulizer, B is the delivery and mixing tube, C is the exposure
chamber along with ports for the animal muzzle temperature and humidity
probe, APS and impinger sampling ports and differential pressure gage port,
D is the plethysmography system, E is the Impinger, F is the APS particle
sizing system, G is the exhaust, H is the exposure port, I is the
humidiﬁer/bubbler, and J is the air supply.
Thus, the sampling from the impinger and APS spectrometer, and
exposure of the animal all occur from the same chamber. Temper-
ature and humidity were monitored once at approximately 5min
into the aerosol generation during each test.
Sampling/monitoring
Aerosol concentration and aerosol particle size distribution were
determined by analysis of atmospheric samples drawn from the
exposure chamber. The atmospheric samples were collected in
an impinger (Model 7541, Ace Glass Inc.) ﬁlled with approx-
imately 20mL of sterile water that sampled at approximately
6.0± 0.3 L/min. The sampling rate was achieved by maintaining a
vacuum of ≥60,955 Pa (or ≥18′′ mercury; Hg) across the exhaust
connectionof the impinger tomaintain theﬂow from the impinger
critical oriﬁce and the sampling ﬂow rate was monitored with a
mass ﬂow meter (MFM, Sierra, Monterey, CA, USA). The MFM
was calibrated prior to use. Each impinger was veriﬁed to operate
properly prior to use using a mini-Buck calibrator® ﬂow meter
(A.P. Buck Inc., Orlando, FL, USA). A new sterile impinger was
used for each test day. The liquid in the impinger was diluted and
enumerated by the spread plate technique to quantify CFU/mL.
Filters (0.45 μm, Nalgene®, Catalog no. 145–0045; Fisher Scien-
tiﬁc, Pittsburgh, PA, USA) were also used to quantify CFU/mL
when the spore concentration in the impinger was anticipated to
be very low (for the 100 and 1,000 inhaled dose targets; see Sample
Analysis). Enumeration results, along with the volume of liquid in
the impinger, sampling rate, and sampling duration, were used in
the calculation of the aerosol concentration expressed as CFU/L
of air.
The aerosol particle size was determined once at approximately
5min into the aerosol generation during each test using an APS
spectrometer, which draws an atmospheric sample from the expo-
sure chamber at 0.25 L/min with a diluter (1.0 L/min total sam-
pling ﬂow with 0.75 L/min from the diluter and 0.25 L/min from
the exposure chamber). An APS was used because of its advan-
tages over othermethods. These advantages include near real-time
data measurements, aerodynamic diameter measurements, ease of
instrument operation, and the generation of electronic data that
is easy to process and export to a report.
Plethysmography
Body plethysmography was performed real-time on each animal
during agent challenge to measure respiratory parameters in the
acute exposure and multiple daily exposure studies. These para-
meters, which included tidal volume (TV), total accumulated TV
(TATV), and minute volume (MV),were calculated from the mea-
sured volumetric displacement of air caused by the movement of
the thoracic cavity of the animal while it was in a sealed cham-
ber called a plethysmograph. The data generated for each animal
was used to determine the TATV, which along with the aerosol
concentration was used in calculating the inhaled dose.
Prior to animal exposures, the plethysmography was calibrated
to establish unit (baseline) and air volume displacements from
5 to 40mL to simulate animal respiration. Rabbits were secured
within a plethysmography restraint device with the head protrud-
ing out of a port that was sealed with rubber dental dam and held
into place with two plexiglass guillotines. The plethysmograph
was connected to a pneumotach (Hans Rudolph, Inc., Kansas City,
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MO, USA) that was attached to a differential pressure transducer
(Model DP-45; Validyne Engineering Corp., North Ridge, CA,
USA). Pressure differential measurements from inhalations and
exhalations were transmitted to Biosystems XA version 1.5.7 soft-
ware (Biosystems XA, Buxco Electronics, Sharon, CT, USA) which
then calculated and recorded respiratory function.
SAMPLE ANALYSIS
Impinger samples were enumerated by the serial dilution (10−1 to
10−3) andplating 0.1mLof eachdilutionon tryptic soy agar (TSA)
plates (Hardy Diagnostics, Santa Maria, CA, USA) in quintupli-
cate. Diluted samples were mixed via vortexing in a capped vial
prior to subsequent dilutions. At each different dilution, 0.1mL
was spread onto each of ﬁve TSA plates, which were placed in
a secondary container and incubated for 24–72 h at 37± 2˚C,
and then enumerated. Impinger samples from the 1× 102 and
1× 103-CFU targeted inhaled doses were enumerated by ﬁlter-
ing 1.0mL of the impinger volume, overlaying the ﬁlter on a TSA
agar plate, performed in quintuplicate and examining the growth
on the ﬁlter. Brieﬂy, 1.0mL of the sample was passed through a
sterile 0.45 μm ﬁlter (Nalgene®) analytical test ﬁlter funnel (Cat-
alog no. 145-0045; Fisher Scientiﬁc, Pittsburgh, PA, USA). The
ﬁlter then was placed face up on top of a TSA plate, incubated
for 24–72 h at 37± 2˚C, and then enumerated. After the incuba-
tion period, the plates were enumerated to determine the average
number of colonies on the replicate plates. The impinger sample
concentration was determined using Eq. 1:
Ci = (A × DF)
0.1 mL
(1)
C i = Impinger sample concentration (CFU/mL)
A =Average CFU per plate (CFU)
DF=Dilution factor (unitless).
INHALED DOSE CALCULATION
The total inhaled dose (Dinh) was calculated from the impinger
sample concentration (C i), impinger sample volume (V i),
impinger sampling rate (S), exposure duration (T ), and total
inhaled TV (V inh) according to the Eq. 2 below. The total number
of viable spores captured during each exposure was the product
of the impinger sample concentration (C i) and the impinger sam-
ple volume (V i). The total number of CFUs was divided by the
amount that was sampled through the impinger during the expo-
sure time (S ×T ). The aerosol concentration (Ca) was (C i ×V i)
(S ×T )−1. The total inhaled dose (Dinh) was the product of the
aerosol concentration multiplied (Ca) by the total inhaled TV
(V inh) as detailed in Eq. 2:
Dinh = [(Ci × Vi)(S × T )−1] × (Vinh) = Ca × Vinh (2)
Dinh =Total inhaled dose (CFU)
C i = Impinger sample concentration (CFU/mL)
V i = Impinger sample volume (mL)
S= Impinger sampling rate (L/min)
T = Exposure duration (min)
V inh =Total inhaled TV (L), as determined by plethysmogra-
phy
Ca =Aerosol concentration (CFU/L).
SPRAY FACTOR
The pilot feasibility testing consisted of performing spray fac-
tor (SF) testing using low concentrations of B. anthracis spores
in the aerosol generator (Collison Nebulizer). This was done to
ensure the challenge system was capable of achieving the low-dose
aerosols that would be required to achieve the low target doses in
the subsequent rabbit studies. The SF is the ratio of the aerosol
concentration to the starting concentration.
The SF can be used as a fundamental indicator to measure
and assess the performance of an aerosol system. The SF is the
ratio of the concentration of agent in the aerosol (aerosol con-
centration, Ca) to the starting concentration used in the aerosol
generator (nebulizer concentration, C s; Hartings and Roy, 2004;
Roy andPitt, 2006). The aerosol concentration is the concentration
obtained from sampling the aerosol, in this case with an impinger,
and enumerating the impinger sample. The SF value is dependent
on the conﬁguration/design of the aerosol system and its opera-
tional parameters and the species or strain of the biothreat agent
aerosolized (Hartings and Roy, 2004; Roy and Pitt, 2006). Any
change to the aerosol system, operational parameters, or the bio-
threat agent could change the SF. The SFwas calculated by dividing
the aerosol concentration (C i ×V i) (S ×T )−1 or Ca by the neb-
ulizer concentration (C s), i.e., the starting nebulizer suspension
concentration, and was used to predict aerosol concentration for
a given starting nebulizer suspension concentration. During SF
pilot testing the overall mean SF was determined for all the neb-
ulizer concentrations examined. The formula for determining the
SF is presented in Eq. 3:
SF = (Ci × Vi) (S × T )
−1
Cs × 1000 (mL/L) =
Ca
Cs
(3)
SF= Spray factor
C i = Impinger sample concentration (CFU/mL)
V i = Impinger sample volume (mL)
S= Impinger sampling rate (L/min)
T = Exposure duration (min)
Ca =Aerosol concentration (CFU/L)
C s =Nebulizer concentration (CFU/L).
In the pilot feasibility SF study, the aerosol system performance
characteristics were evaluated by aerosolizing four target nebulizer
concentrations of B. anthracis spores multiple times over a 3-day
period. The target nebulizer concentrations tested over the 3-
days were 1.0× 104, 1.0× 105, 1.0× 106, and 1.0× 107 CFU/mL.
Speciﬁcally, each concentration was tested a total of nine times
(three times per day over 3 days). Each test consisted of a 10-min
period of aerosol generation and sample collection. The SF values
determined in pilot testing were used to plan the exposures in the
acute and multiple daily exposure studies.
AUTHORIZATION FOR THE USE OF EXPERIMENTAL ANIMALS
All animal work was approved by and performed in accordance
with Battelle’s Institutional Animal Care and Use Committee
(IACUC) and the US Army Medical Research and Materiel Com-
mand Animal Care and Use Review Ofﬁce (ACURO). The studies
were performed in a biosafety level 3 laboratory registeredwith the
Centers of Disease Control and Prevention and inspected by the
Department of Defense and the U.S. Department of Agriculture.
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RESULTS
PILOT FEASIBILITY STUDY
The pilot feasibility study performed SF testing to examine
whether the inhalation system was capable of achieving the low
target doses required for the subsequent rabbit studies. Tar-
get nebulizer concentrations of 1× 104, 1× 105, 1× 106, and
1× 107 CFU/mL were tested in triplicate each day over the 3-
days. Quantiﬁcation of the nebulizers indicated that the enumer-
ated values were up to 30% lower from the target values. As a
result, in an animal study the targeted inhaled doses may not be
achieved if the desired or targeted nebulizer concentrations are
not achieved with the resulting inhaled dose likely off target by
a similar percentage as the nebulizer concentration. This is due
to the fact that there is a direct linear relationship between the
nebulizer concentration and the aerosol concentration. Table 1
shows the mean, standard deviation, and standard error for the SF
for each test day, and for the complete testing with the SF value
of 4.88× 10−7 ± 2.88× 10−7. Overall, the pilot feasibility study
conﬁrmed that the targeted low-doses anticipated in the subse-
quent acute and multiple daily exposure studies were achievable
with a relative standard deviation (RSD) of 63%. Aerosol concen-
tration (as measured via impinger sampling) strongly correlated
with nebulizer concentration (data not shown). The remaining
nebulizer suspensions when enumerated after aerosolization were
found to not be statistically signiﬁcantly higher than the nebu-
lizer concentrations that had been targeted prior to aerosolization,
which indicates that no loss of viable spores hadoccurred as a result
of nebulization process. The data from the pilot feasibility study
was used to plan the subsequent single and multiple challenge day
rabbit studies required nebulizer concentrations and how much
test atmosphere the rabbits needed to inhale to reach the desired
doses.
Additional information was generated on the aerosol particle
size (mass median aerodynamic diameter,MMAD) for each of the
four nebulizer concentrations tested during the feasibility study.
Using the APS spectrometer, the MMAD for the aerosol gener-
ated from each of the B. anthracis nebulizer suspensions at each
Table 1 | Pilot feasibility study mean spray factor data.
Target nebulizer
concentration (CFU/mL)
Spray factor
Day 1 Day 2 Day 3
1×104 4.62×10−7 1.67×10−7 9.32×10−7
1×105 5.35×10−7 4.20×10−7 6.12×10−7
1×106 4.22×10−7 1.82×10−7 6.37×10−7
1×107 3.14×10−7 1.50×10−7 6.66×10−7
Mean 4.33×10−7 2.30×10−7 7.11×10−7
Standard deviation 1.40×10−7 2.73×10−7 2.06×10−7
Standard error 4.05×10−8 7.88×10−8 5.95×10−8
Overall mean 4.58×10−7
Overall % relative standard
deviation
63
Overall standard deviation 2.88×10−7
Overall standard error 4.80×10−8
concentration varied from 0.83 to 1.06μm with geometric stan-
dard deviation (GSD) of 1.53 or lower (1.40–1.53). The MMAD
values increased as the nebulizer concentration increased. This
effect was most likely due to the fact that the APS spectrome-
ter analyzes and sizes all particles sampled and counted by the
instrument. The APS spectrometer does not distinguish between
water droplets, debris particles, spores, etc. As a result, a greater
proportion of small water droplet and debris were likely counted
relative to spores at the lower B. anthracis spore concentrations
aerosolized. As the spore concentration increased in the nebu-
lizer, a greater proportion of B. anthracis spores were aerosolized
and thus analyzed by the APS compared to water droplets and
debris, thereby accounting for a larger percent of the total mass.
The result was a shift to a larger measured particle size or MMAD.
This effect occurred until a spore concentration was reached in
the aerosol where the majority of particles counted and sized were
only spores and the MMAD reﬂected predominately individual
spores. Regardless, the aerosol particle sizes obtained during test-
ing were particle size ranges that can reach the rabbit or human
deep lung alveoli. The same trend phenomenon was seen with the
aerosol particle sizes in the acute single day exposure and multiple
daily exposure studies.
ACUTE SINGLE DAY INHALATION EXPOSURE STUDY
In the acute study, four groups of ﬁve rabbits were aerosol
challenged to deliver targeted inhaled doses of 1× 102, 1× 103,
1× 104, and 1× 105 CFU of B. anthracis spores. Nebulizer con-
centrations used to achieve the desired doses were targeted to be
1× 104, 1× 105, 1× 106, and 1× 107 CFU/mL based off of the
feasibility study SF testing. Plate counts of the impinger sam-
ples revealed that mean actual inhaled doses per group were
2.86× 102 (±4.32× 101), 2.06× 102 (±3.42× 102), 2.53× 102
(±5.21× 103), to 2.75× 105 (±7.41× 104) CFU, which were
slightly higher than the target inhaled doses. The primary causes
for the higher actual dose delivered from the target dose were the
starting nebulizer concentrations which were higher than antici-
pated, and the SF value, which was higher compared to what was
determined in the pilot feasibility study. The mean SF and stan-
dard deviation was determined to be 1.26× 10−6 ± 1.35× 10−7
(individual data not shown) with a standard error of 6.28× 10−8
and a RSD of 22%. This mean SF is 2.7 times higher than the mean
SF determined in the pilot feasibility study. The nebulizer concen-
trations were 1.37- to 1.96-fold higher than the targeted nebulizer
concentrations. Figure 2 illustrates the group mean inhaled chal-
lenge doses for the test day. The ﬁgure illustrates the group mean
inhaled dose (bars) and standard deviation against the targeted
dose (dashed lines). Additionally, the ﬁgure shows that while the
inhaled doses were slightly higher than target and the increase
above the target was relatively consistent across the four doses. The
mean MMAD for challenge material for each group as determined
by anAPS spectrometer readings varied from 0.82 to 1.12μmwith
GSD of 1.33 to 1.57, and with a trend that the MMAD increased
as the nebulizer concentration increased.
MULTIPLE DAILY INHALATION EXPOSURE STUDY
Three groups of seven rabbits were exposed to targeted inhaled
doses of 1× 102, 1× 103, and 1× 104 CFU during the multiple
Frontiers in Cellular and Infection Microbiology www.frontiersin.org June 2012 | Volume 2 | Article 71 | 5
Barnewall et al. Achieving low-dose inhalation exposures
FIGURE 2 | Mean acute single day low-dose inhalation challenge data.
The ﬁgure illustrates the mean inhaled dose (bars) with standard deviation
compared to the target doses (dashed horizontal log increment lines). The
low-dose target was 102, the mid-dose1 target was 103, the mid-dose 2
target was 104, and the high-dose target was 105.
daily inhalation exposure study. Figure 3 illustrates the group
mean challenge daily doses over the 15 challenge days. The ﬁgure
illustrates the daily group mean inhaled dose (bars) and stan-
dard deviation against the targeted dose (dashed lines). The daily
mean group inhaled dose values oscillate around the target dose.
All challenge days had consistent dosing except Challenge Day 3
where the challenge dose of 1× 102 CFUwas higher than expected.
This increase was most likely caused by an error in the dilution
of the challenge material. The actual mean doses for all 15 days
were approximately 1.13–3.08 times the targeted inhaled dose and
remained relatively consistent from animal to animal, which was
very similar to the results obtained in the acute exposure study.
Plate counts of the impinger samples revealed that individual
mean actual inhaled doses of the 15-days of challenge ranged from
2.32× 102 (±1.28× 101) to 1.44× 104 (±5.99× 103) CFU. Sim-
ilar to the acute exposure study results, the primary causes for the
higher actual dose delivered from the target dose were the start-
ing nebulizer concentrations, which were higher than anticipated,
and the SF value, which was higher compared to what was deter-
mined in the pilot feasibility study. The mean SF and standard
deviation was determined to be 1.13× 10−6 ± 5.28× 10−7 (indi-
vidual data not shown and day 2 low-dose data excluded) with
a standard error of 3.11× 10−8 and a RSD of 48%. This mean
SF is 2.5 times higher than the mean SF determined in the pilot
feasibility study and similar to the SF results for the acute single
day study. Although the starting nebulizer concentrations were
higher than the target concentrations, it was determined that the
volume of test atmosphere each rabbits was to inhale was not to
be adjusted in order for method consistency with the acute single
exposure study. The nebulizer concentrations were 1.15- to 1.32-
fold higher than the targeted nebulizer concentrations. The mean
MMAD for challenge material for each group for all 15 days as
determined by an APS spectrometer readings varied from 0.79 to
0.86μmandGSDof 1.43 to 1.61, andwith the trend that themean
FIGURE 3 | Mean 15day low-dose inhalation challenge data.The ﬁgure
illustrates the mean inhaled dose (bars) with standard deviation compared
to the target dose (dashed horizontal log increment lines). The low-dose
target was 102, the mid-dose target was 103, and the high-dose target
was 104.
group MMAD increased as the nebulizer concentration increased
across all test days. Figure 4 is a log distribution plot of each
group’s mean MMAD and GSD along with a representative parti-
cle distribution graph from theAPS spectrometer for the low-dose
group.
DISCUSSION
These studies are the ﬁrst known concerted effort to develop
and deliver low-doses of B. anthracis spores via inhalation in a
reproducible manner. The pilot feasibility study (see Table 1 for
results) enabled the characterization of the aerosol system’s abil-
ity to deliver low-doses which were conﬁrmed in the acute and
multiple daily inhalation exposure studies.
The pilot feasibility study determined a SF value when
aerosolizing low concentrations of B. anthracis spores. The SF
value is a unitless factor that represents the aerosol dilution that
is to be expected during an aerosol experiment using the same
biological agent in the same aerosol system (Roy and Pitt, 2006).
In theory, the aerosol system should always generate the same
mean SF or fall within the same range time for the material being
aerosolized. Based on the SFs from the pilot feasibility study, it
was determined that within an aerosol day the mean SF value
could be ±2.3 times the target value and between days of ±5.6
times the target value which would cause the inhaled dose in
an animal study to have the same variability. The RSD for the
acute and 15-day study were 22 and 48%, respectively, which both
fall within the 63% that was determined in the pilot feasibility
study.
One must also consider that the nebulizer concentration and
impinger concentration used in determining the SF value and the
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FIGURE 4 | Log distribution plot of the MMAD and GSD for the
multiple exposure day study along with a representative particle
distribution graph from the APS for the low-dose group.
calculated dose delivered to an animal, respectively, are gener-
ated using the spread plate technique which has its own inher-
ent variability. As a result, any problems such as a diluting
error or plating the incorrect dilution, affects the nebulizer or
impinger results, and will, in turn, affect the SF, and inhaled dose
calculations.
In addition to the use of the SF as a tool to assess the perfor-
mance of the aerosol system, the SF can be utilized in two other
ways. First, the SF can be used to determine the nebulizer con-
centration (C s) needed to administer a speciﬁc total inhaled dose
(Dinh) over a ﬁxed exposure time. For example, what nebulizer
concentration (C s) would be needed for a 10-min exposure if the
target total inhaled dose (Dinh) were 1× 106 CFU, and a histori-
cal SF of 1.0× 10−6 were used? If rabbits were aerosol challenged
with B. anthracis spores for a 10-min exposure time (T ), and
each rabbit’s MV (V min) were 1.0 L per minute, then T ×V min
(10min× 1.0 L/min) would yield a total inhaled volume (V inh)
of 10 L. The necessary starting nebulizer concentration (C s) based
on the information to achieve the total inhaled dose (Dinh) is
calculated as follows:
Vinh × Ca = Dinh
10(L) × Ca = 1 × 106(CFU)
Ca = 1 × 106(CFU)/10(L) = 1 × 105(CFU/L)
SF = Ca
/
Cs
1 × 10−6 = 1 × 105(CFU/L) × C−1s
Cs = 1 × 105(CFU/L)/1 × 10−6 = 1 × 1011(CFU/L) or 1
× 109(CFU/mL)
(4)
Alternatively, with biological agents for which the concentra-
tion can be determined prior to the inhalation exposure, the SF can
be used to determine the total TV (V inh) an animal must inhale
to reach the target inhaled dose (Dinh). In this scenario, the MV
(V min) of the animal is not known prior to challenge and is mea-
sured real-time during the exposure using plethysmography. As
a consequence, all animals would inhale the same volume (V inh)
of atmosphere and the exposure time (T ) would vary based in
each animal’s particular MV (V min). For example, from a histor-
ical SF of 1.0× 10−6, the starting nebulizer concentration (C s)
may be determined to be 1× 109 CFU/mL prior to challenge to
achieve the target inhaled dose (Dinh) of 1× 106 CFU. The nec-
essary volume of aerosol to inhale (V inh) is calculated as follows.
Based on the SF and starting concentration, the assumed aerosol
concentration (Ca) will be:
Ca = SF × Cs = 1 × 10−6 × (1 × 109 CFU/mL)
= 1 × 103 CFU/mL or 1 × 106 CFU/L
Vinh = Dinh
/
Ca = 1 × 106(CFU)/1 × 106(CFU/L) = 1L
(5)
The advantage of conducting aerosol exposures using this sec-
ond scenario compared to the ﬁrst is that the precision and accu-
racy of achieving the target total inhaled dose is increased and the
standard deviation of the mean of the total inhaled doses (mean
Dinh) delivered to all the animals will be decreased. The primary
cause for the larger standard deviation in ﬁrst scenario is due to the
inherent variability of the MV (V min) among the animals. Thus, if
the aerosol concentration is the same from exposure to exposure,
and an animal with a V min of 1 L per minute will receive/inhale
twice the dose of an animal with a V min of 0.5 L per minute. This
effect is negated or reduced in the second scenario because all the
animals are inhaling the same volume of aerosol but with different
exposure times (Hartings and Roy, 2004). Several previous studies
using this approach for designing B. anthracis exposure studies
conﬁrm this second approach is precise and accurate (Little et al.,
2004; Klas et al., 2008; Migone et al., 2009).
These studies demonstrate how the total inhaled volume (V inh),
as determined by plethysmography, can be used to calculate
inhaled dose (Dinh). One of the primary factors for the consistency
of the inhaled dose delivered in these exposure studies was from
the real-time monitoring and recording of respiratory parameters,
in particular, V min and V inh during the exposure, via plethys-
mography. As indicated previously (Hartings and Roy, 2004; Roy
and Pitt, 2006), performing plethysmography real-time minimizes
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the variability resulting from individual rabbit’s respiratory V min
compared to performing exposure of a deﬁned time limit. Had a
deﬁned exposure time limit been used, the predicted dose received
per animal and mean per dose group would have been approxi-
mately 30% higher and with a larger standard deviation. Not all
institutions perform real-time plethysmography and these studies
are the ﬁrst to use real-time plethysmography when performing
low-dose exposures over multiple days, demonstrating its value to
inhalation research.
Previous published data have used a similar descriptive term
as SF called the aerosolization ratio. The aerosolization ratio is
determined by dividing the total concentration of aerosolized
organisms (CFU/m3) by the total concentration of organisms in
the ﬂuid (CFU/mL; Wang et al., 2004; Barth et al., 2009). When
the total concentration of aerosolized organisms is converted to L
in the aerosolization ratio (m3 = 1000 L), the aerosolization ratio
calculation is the same as the SF. The SF values generated in these
studies cannot be compared to the aerosolization ratios since both
the SF and aerosolization ration are dependent on the conﬁgura-
tion/design of the aerosol system, its operational parameters, and
the species/strain of the biothreat agent aerosolized.
The aerosol concentration can be altered (raised or lowered) by
manipulations of the aerosol system. These manipulations include
changing the aerosol generator, varying the output of the aerosol
generator, varying the concentration of the material in the aerosol
generator, and varying the dilution air. For the acute and multiple
daily dose studies, it was most important to maintain consistency
and to follow the same standard operating procedure in each study
and on each study day. Therefore, adjusting the concentration of
B. anthracis spores in the Collison nebulizer was selected as the
most reliable procedure to ensure consistent results.
In the acute single day study, rabbits were exposed to targeted
inhaled doses of 1× 102, 1× 103, 1× 104, and 1× 105 CFU of B.
anthracis spores. The actual doses were approximately 2.06–2.86
times the targeted inhaled dose and remained relatively consistent
from animal to animal. In the multiple daily exposure study, rab-
bits were exposed to targeted inhaled doses of 1× 102, 1× 103, and
1× 104 CFU of B. anthracis spores. The actual mean doses for all
15 days were approximately 1.13–3.08 times the targeted inhaled
dose and remained relatively consistent from animal to animal,
which was very similar to the results obtained in the acute expo-
sure study. The variability seen in the animal doses for both the
acute single day study and 15 day study were within the predicted
variability of the SF feasibility testing. One of the contributing fac-
tors for the higher than targeted doses the animals achieved was
the higher than anticipated concentrations of spores in the Colli-
son nebulizer. In both studies the nebulizer concentrations were
1.15–1.96 times higher than the target concentration. In spite of
the higher nebulizer concentrations and the resultant higher doses
delivered to the animals, the dose results presented in Figure 3
show that exposures produced by the aerosol system were stable
and reproducible from day-to-day.
In all testing, the aerosol system produced aerosolized spores
with MMAD particle sizes in all tests that were in a size range
that can reach the rabbit deep lung alveoli. Additionally, it was
demonstrated that the distribution of the aerosol was monodis-
persed as indicated by GSD less than 2.0. The biological effects of
inhaled aerosols can be dependent upon the sites and degree of
deposition within the respiratory tract. Further, the size and shape
of inhaled aerosols is a critical factor in determining deposition
mechanisms and the extent of penetration into the lung and alve-
olar regions. Aerosols with aerodynamic particle sizes between
1 and 5μm are suitable for inhalation studies in order to reach
(Schlesinger, 1985; Hinds, 1999) and cause disease in the deep
lung. Above this size, a larger portion of the aerosol is deposited in
the upper respiratory tract (Schlesinger, 1985; Hinds, 1999). Large
particles containing biological agents deposited in the upper respi-
ratory tractmaynot cause disease,ormay require a higher quantity
(dosage) to cause disease or may cause only an upper respiratory
disease. Therefore, if a study objective is to maximize deep lung
deposition, then an aerosol with a size on the order of 1–5μm
or lower is required; this range was attained throughout the three
studies.
These studies have shown that with thorough characterization,
traditional bioaerosol generation and collection techniques can be
employed to achieve consistent and reproducible low-dose expo-
sures within a day and between multiple test days in the animal
model system. The data presented in this manuscript represent the
ﬁrst known study to show the repeatability of low-dose inhalation
B. anthracis spore exposures.
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